How to Deal with Eligibility Creep in Immune-Mediated Inflammatory Disorders Studies

(This is part 1 of a 3-part series on Inflammatory Disorders Studies. View part 2 here.View the complete series in our Inflammation eBook.

Placebo response rates can obscure treatment effects, putting effective drugs at risk

One of the confounding factors in clinical studies that can contribute to difficulty in Inflamation Blog Covance Patientdiscriminating an active treatment effect versus placebo is subject eligibility creep when subjects (e.g. with milder forms of disease severity at baseline) may get enrolled inappropriately by sites when struggling to meet recruitment targets and timelines. Baselines are skewed and misrepresented since subjects initially may be assessed as suffering from the more severe disease grades required to meet inclusion criteria.

The inclusion of de facto milder patients can make it more difficult to observe a treatment difference versus placebo and is, unfortunately, likely to place the trial at significant risk of failure. Multiple other factors also play a role in the so-called placebo response; placebo response rates of 14 to 20% have been observed in trials such as psoriasis, and nearly 30% in placebo-controlled studies in rheumatoid arthritis. Even higher rates have been observed in ulcerative colitis studies. High placebo response can result in a failure to observe treatment effects and place otherwise effective drugs at risk of the study not meeting the primary endpoint.

In addition, Immune-Mediated Inflammatory Disorders (IMIDs) have a tendency to have unpredictable, chronic remitting and relapsing patterns. This makes it crucial to confirm severity and ensure stable disease at baseline on at least two separate assessments and with follow up treatment evaluations conducted by the same evaluator throughout the study to control standardization and mitigate assessment variability. Specific training of site staff who will be performing certain study assessments, such as ACR20 assessments in rheumatoid arthritis studies, is critical. The training is a way to reduce variability of patient assessments across sites and regions and ensure greater standardization across the study to provide more robust data. Blinded, standardized, centralized reading of some assessments, e.g. long-term radiographic evaluations, is likewise a valuable tool to help minimize bias and endpoint variability.

The key to combating eligibility creep is to bear these challenges and the natural history of the disease when recruiting subjects and proactively putting in place the measures aimed at improving the quality of enrollment and the rigorous standardization of baseline and endpoint assessments.

Visit our website for information on inflammation drug development.  

Download our Inflammation eBook. 

This entry was posted in Clinical Testing and tagged , , by Joan Meyer, Ph.D.. Bookmark the permalink.

About Joan Meyer, Ph.D.

Joan Meyer, Ph.D., is the Operational Strategy & Planning Global Therapeutic Area Head for Inflammation, Infectious Diseases, and General Medicine at Covance. Dr. Meyer has more than 25 years of pharmaceutical and CRO experience, holding leadership positions in project management, strategic marketing, and study start-up. She has also served in leadership roles in the Ohio River Valley and National Arthritis Foundations. Dr. Meyer graduated from St. Mary’s University, Minnesota, with a BA in Biology and BA in Psychology. She received her Master of Science and Ph.D. in Neuroscience from the University of Illinois at Urbana-Champaign, where she taught in the College of Medicine.